The goal of this proposal is to understand the role of class IA phosphatidylinositol 3‐kinase (PI3K) p110alpha and p110beta in regulating pathological and physiological cell growth in the pancreas and skeletal muscle. These two class IA PI3Ks are postulated to control protein synthesis and cell growth and survival. However, it has not been possible to investigate the biological roles of these enzymes using whole‐body gene deletion due to embryonic lethality. To overcome this experimental problem, mouse strains in which the two PI3K genes can be selectively deleted in specific tissues were generated. Using these animals, this proposal addresses four research questions.
Aim 1 determines if pancreas‐specific ablation of p110alpha or p110beta blocks the formation of pancreatic tumors induced by constitutively active KrasG12D. Mice with pancreas‐specific expression of KrasG12D develop the full spectrum of malignant intraepithelial lesions commonly found in human pancreatic cancer. In addition, a fluorescence spectroscopy technique is used to measure the binding affinity between activated Kras and PI3K complexes containing p110alpha or p110beta, which might provide mechanistic insight into the phenotypes seen in the two knockout strains.
Aim 2 investigates how insulin‐like growth factor‐1 (IGF‐1) activates mammalian target of rapamycin (mTOR) signaling in myotubes prepared from muscle‐specific p110alpha knockout mice. IGF‐1 activation of PI3K and then mTOR is thought to be a central regulatory signal for stimulating muscle growth. These studies pursue the molecular mechanisms that explain the unexpected finding of enhanced mTOR signaling in response to IGF‐1 in p110alpha‐null muscle, even though Akt activation is greatly reduced.
Aim 3 investigates if ablation of p110alpha or p110beta affects skeletal muscle atrophy caused by hindlimb unloading or muscle regrowth following reambulation. This animal model mimics the process of muscle unloading and reloading that can occur during hospitalization. The degree of muscle atrophy and subsequent regrowth is monitored by microCT scans of muscle mass in the same animal.
Aim 4 also uses microCT scans to determine if clenbuterol, a beta2 adrenergic receptor agonist known to promote muscle growth in humans and rodents, can still stimulate muscle hypertrophy in muscle‐specific p110alpha or p110beta knockout mice. Clenbuterol signaling to mTOR is also investigated in myotubes prepared from knockout mice. Knowledge gained from these experiments is important because drugs that inhibit PI3K are already being tested in clinical trials for the treatment of cancer. The identification of cancer patients who will respond to this targeted signal transduction therapy remains a major challenge. Moreover, systemic inhibition of PI3K runs the risk of adverse side effects if these enzymes play important roles in regulating organ function, including maintenance of muscle mass.

Public Health Relevance

Pancreatic cancer is a deadly disease with little efficacious treatment. One goal of this project is to understand if phosphatidylinositol 3-kinase (PI3K) plays a role in the development of this cancer. Muscle atrophy is a major health problem, with effects ranging from reduced physical activity to severely impaired mobility, that can have severe medical and financial consequences on patients and their families. Another goal of this project is to understand if PI3K plays a role in controlling muscle wasting and growth. These studies will increase our knowledge about how alterations in PI3K signaling contribute to the development of these health problems and lead to better treatment of these conditions.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Molecular and Integrative Signal Transduction Study Section (MIST)
Program Officer
Abraham, Kristin M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
State University New York Stony Brook
Internal Medicine/Medicine
Schools of Medicine
Stony Brook
United States
Zip Code
Wu, Chia-Yen C; Chen, Biyi; Jiang, Ya-Ping et al. (2014) Calpain-dependent cleavage of junctophilin-2 and T-tubule remodeling in a mouse model of reversible heart failure. J Am Heart Assoc 3:e000527
Wu, Chia-Yen C; Carpenter, Eileen S; Takeuchi, Kenneth K et al. (2014) PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 147:1405-16.e7
Nelson, Victoria L B; Jiang, Ya-Ping; Dickman, Kathleen G et al. (2014) Adipose tissue insulin resistance due to loss of PI3K p110? leads to decreased energy expenditure and obesity. Am J Physiol Endocrinol Metab 306:E1205-16
Kanakia, Shruti; Toussaint, Jimmy D; Mullick Chowdhury, Sayan et al. (2014) Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations. Biomaterials 35:7022-31
Lu, Zhongju; Wu, Chia-Yen C; Jiang, Ya-Ping et al. (2012) Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med 4:131ra50
Jaber, Nadia; Dou, Zhixun; Chen, Juei-Suei et al. (2012) Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci U S A 109:2003-8
Chattopadhyay, Mohar; Selinger, Elzbieta S; Ballou, Lisa M et al. (2011) Ablation of PI3K p110-? prevents high-fat diet-induced liver steatosis. Diabetes 60:1483-92
Lu, Zhongju; Ballou, Lisa M; Jiang, Ya-Ping et al. (2011) Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-ýý. J Cardiovasc Pharmacol 58:439-45
Wu, Chia-Yen C; Jia, Zhiheng; Wang, Wei et al. (2011) PI3Ks maintain the structural integrity of T-tubules in cardiac myocytes. PLoS One 6:e24404
Dou, Zhixun; Chattopadhyay, Mohar; Pan, Ji-An et al. (2010) The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. J Cell Biol 191:827-43

Showing the most recent 10 out of 25 publications